IOVA (Iovance Biotherapeutics) LT-Debt-to-Total-Asset : 0.05 (As of Dec. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Iovance Biotherapeutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Iovance Biotherapeutics's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.05.

Iovance Biotherapeutics's long-term debt to total assets ratio declined from Dec. 2023 (0.09) to Dec. 2024 (0.05). It may suggest that Iovance Biotherapeutics is progressively becoming less dependent on debt to grow their business.

Iovance Biotherapeutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Iovance Biotherapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Iovance Biotherapeutics LT-Debt-to-Total-Asset Chart

Iovance Biotherapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.06

0.09

0.11

0.09

0.05

Iovance Biotherapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.09	0.08	0.07	0.07	0.05

Iovance Biotherapeutics LT-Debt-to-Total-Asset Calculation

Iovance Biotherapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	45.365	/	910.426
	=	0.05

Iovance Biotherapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	45.365	/	910.426
	=	0.05

Iovance Biotherapeutics (NAS:IOVA) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Iovance Biotherapeutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Iovance Biotherapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Iovance Biotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Iovance Biotherapeutics Inc (NAS:IOVA) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

0JDK:UK 2LB:Germany

Address

825 Industrial Road, Suite 400, San Carlos, CA, USA, 94070

Website

https://www.iovance.com

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Executives

Ryan D Maynard	director	RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Wayne P. Rothbaum	director	C/O QUOGUE CAPITAL LLC, 1285 AVENUE OF THE AMERICAS, 35TH FLOOR, NEW YORK NY 10019
Merrill A Mcpeak	director	PO BOX 500 (M/S 55-985), 14200 SW KARL BRAUN DRIVE, BEAVERTON OR 97077-0001
Wendy L Yarno	director
Frederick G Vogt	officer: General Counsel	2120 HEMLOCK RD., WEST NORRITON PA 19403
Iain D. Dukes	director	112 W. 34TH STREET, 17TH FLOOR, NEW YORK NY 10120
Wendy L Dixon	director
Michael Weiser	director	C/O SPACES, SUITE 265, 3350 VIRGINIA STREET, MIAMI FL 33133
Igor Bilinsky	officer: Chief Operating Officer	C/O VICAL INCORPORATED, 10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Jean-marc Bellemin	officer: Chief Financial Officer	C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Michael Swartzburg	officer: VP, Finance	C/O AVALANCHE BIOTECHNOLOGIES, INC., 1035 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025
Athena Countouriotis	director	C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Finckenstein Friedrich Graf	officer: Chief Medical Officer	999 SKYWAY ROAD, SUITE 150, SAN CARLOS CA 94070
Timothy E Morris	officer: Chief Financial Officer	ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Maria Fardis	director, officer: President and CEO	C/O PARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085